Dashboard
Manage Tickers

REGN REGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 755.83 $ 18.90 (2.56 %)    

Friday, 21-Nov-2025 15:56:39 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 589.60 $ 4.40 (0.75 %)
DIA $ 462.45 $ 5.05 (1.1 %)
SPY $ 658.47 $ 6.50 (1 %)
TLT $ 89.50 $ 0.27 (0.3 %)
GLD $ 373.70 $ -0.58 (-0.15 %)
$ 755.9
$ 736.01
$ 757.67 x 1
$ 758.56 x 1
$ 739.16 - $ 764.01
$ 475.17 - $ 796.57
1,427,897
na
79.44B
$ 0.71
$ 17.35
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-28-2025 09-30-2025 10-Q
2 08-01-2025 06-30-2025 10-Q
3 04-29-2025 03-31-2025 10-Q
4 02-05-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-05-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-06-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-07-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-08-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-07-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-07-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 02-08-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-09-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

alphabet-exact-sciences-and-regeneron-are-among-the-top-10-large-cap-gainers-last-week-nov-17-nov-21-are-the-others-in-your-portfolio
Alphabet, Exact Sciences, And Regeneron Ar...
11/23/2025 13:31:18

Discover last week's top 10 large-cap stock gainers, why they rallied, and what catalysts drove Alphabet, Exact Sciences, R...

no-ones-buying-homes-here-cramer-warns-on-this-housing-stock
'No One's Buying Homes Here': Cramer Warns...
11/21/2025 18:51:40

Cramer prefers Netflix (NFLX) over FuboTV (FUBO). Rocket Companies (RKT) and Regeneron Pharmaceuticals (REGN) also discussed. F...

tech-stocks-fall-despite-nvidias-beat-walmart-jumps-6-whats-moving-markets-thursday
Tech Stocks Fall Despite Nvidia's Beat, Wa...
11/20/2025 17:43:19

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lif...

regeneron-wins-fda-nod-for-eylea-hd-with-reduced-injection-schedule-for-patients-with-vision-loss
Regeneron Wins FDA Nod For Eylea HD With R...
11/20/2025 16:52:15

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across...

wells-fargo-maintains-equal-weight-on-regeneron-pharmaceuticals-raises-price-target-to-700
Wells Fargo Maintains Equal-Weight on Rege...
11/20/2025 15:40:42

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price ...

trading-halt-halt-status-updated-at-42500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 4:25:...
11/19/2025 21:25:04

regeneron-pharmaceuticals-gets-fdas-approval-for-its-eylea-hd-injection-8-mg-to-treat-macular-edema-following-retinal-vein-occlusion
Regeneron Pharmaceuticals Gets FDA's Appro...
11/19/2025 21:11:10

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYL...

trading-halt-halted-at-40500-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:05:00 p.m. ET - ...
11/19/2025 21:05:04

regeneron-announes-european-commission-approval-of-libtayo-for-adjuvant-treatment-of-cutaneous-squamous-cell-carcinoma-patients-at-high-risk-of-recurrence-after-surgery-and-radiation
Regeneron Announes European Commission App...
11/19/2025 12:10:52

fear-of-an-ai-bubble-this-sector-is-quietly-surging-while-tech-sinks
Fear Of An AI Bubble? This Sector Is Quiet...
11/14/2025 20:17:19

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

governor-hochul-announces-regeneron-to-invest-more-than-2-billion-into-saratoga-county-facility-creating-1000-new-jobs
Governor Hochul Announces Regeneron to Inv...
11/13/2025 19:47:56

https://www.governor.ny.gov/news/governor-hochul-announces-regeneron-invest-more-2-billion-saratoga-county-facility-creating

wall-street-falls-on-us-government-reopening-day-bitcoin-slides-to-100000-whats-moving-markets-thursday
Wall Street Falls On US Government Reopeni...
11/13/2025 17:37:18

Risk sentiment deteriorated sharply on Thursday despite federal agencies reopening after the longest government shutdown in U.S...

crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial
CRISPR Therapeutics' Investigational Gene ...
11/11/2025 14:50:51

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its...

reported-saturday-regeneron-reports-robust-anti-clotting-effects-for-regn7508cat-and-regn9933a2-in-total-knee-replacement-patients-with-no-clinically-relevant-bleeding
Reported Saturday, Regeneron Reports Robus...
11/10/2025 09:13:33

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies agains...

ubs-maintains-neutral-on-regeneron-pharmaceuticals-raises-price-target-to-660
UBS Maintains Neutral on Regeneron Pharmac...
11/07/2025 17:52:48

UBS analyst Trung Huynh maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $5...

regeneron-pharmaceuticals-trial-data-from-liberty-afrs-aims-phase-3-study-shows-dupixent-improves-signs-symptoms-of-allergic-fungal-rhinosinusitis-reduces-sinus-opacification-nasal-congestion-and-nasal-polyps
Regeneron Pharmaceuticals Trial Data From ...
11/07/2025 13:11:51

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the pivotal...

regeneron-presents-results-showing-liberty-afrs-aims-phase-3-trial-of-dupixent-met-all-primary-and-secondary-endpoints
Regeneron PResents Results Showing LIBERTY...
11/07/2025 13:08:00

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
11/06/2025 15:30:59

looking-into-regeneron-pharmaceuticals-incs-recent-short-interest
Looking Into Regeneron Pharmaceuticals Inc...
11/04/2025 19:00:36

rbc-capital-maintains-sector-perform-on-regeneron-pharmaceuticals-raises-price-target-to-708
RBC Capital Maintains Sector Perform on Re...
10/29/2025 16:56:39

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the pr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION